Wide Ranks

DYAI

Dyadic International, Inc.

1.87

Top Statistics
Market Cap 55 M Forward PE -5.84 Revenue Growth -53.90 %
Current Ratio 5.39 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue 16.11 Price To Sales Trailing12 Months 30.67
Profitability
Profit Margins 0.00 % Operating Margins -528.50 %
Balance Sheet
Total Cash 10 M Total Cash Per Share 0.3430 Total Debt 5 M
Total Debt To Equity 175.65 Current Ratio 5.39 Book Value Per Share 0.2040
All Measures
Short Ratio 673.00 % Message Board Id finmb_4272801 Fax 561 743 8343
Shares Short Prior Month 133920 Return On Equity -1.27 City Jupiter
Uuid ca82c55d-767c-3c45-bb16-d70d0b54b7aa Previous Close 1.73 First Trade Date Epoch Utc 1 B
Book Value 0.2040 Beta 0.7210 Total Debt 5 M
Volume 74076 Price To Book 9.17 Fifty Two Week Low 0.9300
Total Cash Per Share 0.3430 Total Revenue 1 M Shares Short Previous Month Date 1 B
Target Median Price 7.50 Audit Risk 4 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -528.50 % Target Mean Price 7.50
Net Income To Common -7740876 Short Percent Of Float 0.0089 Implied Shares Outstanding 29 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 121510
Average Volume10days 121510 Total Cash 10 M Next Fiscal Year End 1 B
Revenue Per Share 0.0620 Held Percent Insiders 0.3021 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 9
Regular Market Previous Close 1.73 Target Low Price 6.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 1.18 Open 1.75 Free Cashflow -3489311
State FL Dividend Yield 0.00 % Return On Assets -0.4628
Time Zone Short Name EST Board Risk 6 Trailing Eps -0.2300
Day Low 1.61 Address1 1044 North U.S. Highway One Shares Outstanding 29 M
Compensation Risk 7 Price Hint 4 Target High Price 9.00
Website https://www.dyadic.com 52 Week Change 0.1065 Average Volume 39004
Forward Eps -0.3200 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 532.50 % Is_sp_500 False Regular Market Day High 1.89
Profit Margins 0.00 % Debt To Equity 175.65 Fifty Two Week High 2.67
Day High 1.89 Shares Short 178622 Regular Market Open 1.75
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 16.11
Revenue Growth -53.90 % Shares Percent Shares Out 0.0061 Operating Cashflow -5962455
Currency USD Time Zone Full Name America/New_York Market Cap 55 M
Is_nasdaq_100 False Zip 33477-5094 Quote Type EQUITY
Industry Biotechnology Long Name Dyadic International, Inc. Overall Risk 7
Regular Market Day Low 1.61 Held Percent Institutions 0.1601 Current Price 1.87
Address2 Suite 201 Financial Currency USD Current Ratio 5.39
Gross Margins 50.01 % Industry Disp Biotechnology Number Of Analyst Opinions 2
Country United States Float Shares 18 M Two Hundred Day Average 1.46
Governance Epoch Date 1 B Enterprise Value 29 M Price To Sales Trailing12 Months 30.67
Forward PE -5.84 Regular Market Volume 74076 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally.

It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.

The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform.

It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness.

The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.

; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd.

, Alphazyme, LLC, and Abic Biological Laboratories Ltd.

Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.